Previous 10 | Next 10 |
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2024-01-02 12:56:48 ET More on Mid-day movers & stocks. ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Endra Life Sciences Historical earnings da...
2024-01-02 08:40:41 ET More on Anavex Life Sciences How Soon Might Anavex's Alzheimer's Drug Be Approved? The Good/Bad News Anavex Life Sciences: Rett Safety Dance With Broader CNS Implications (Rating Downgrade) Anavex Life Sciences Corp. (AVXL) Q4 2023 Earnings Cal...
2024-01-02 08:30:21 ET Losers: Corcept Therapeutics CORT -33% in patent battle with Teva . China SXT Pharmaceuticals ( SXTC ) -29% . Sentage Holdings ( SNTG ) -27% . China Green Agriculture ( CGA ) -23% . Aditxt ( ADTX ) -24% . ...
Anavex Announces Topline Results from Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome Validation from Real World Evidence (RWE) of Rett Syndrome Patients under Compassionate Use Authorization NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp....
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...
2023-12-19 17:03:56 ET More on Anavex Life Sciences How Soon Might Anavex's Alzheimer's Drug Be Approved? The Good/Bad News Anavex Life Sciences: Rett Safety Dance With Broader CNS Implications (Rating Downgrade) t Anavex Life Sciences falls after Q4 pipeline upd...
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders,...
2023-12-05 03:58:10 ET Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anav...
2023-11-29 07:21:25 ET Summary The EU recommends Anavex proceed with a full approval application for Alzheimer's drug Blarcamesine based on full Phase 2b/3 trial data. The U.S. FDA may grant accelerated approval to Anavex's Blarcamesine based on biomarker data alone. Blarcamesine ...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...